{"title":"HeartSmart ® for routine optimization of blood flow and facilitation of early goal-directed therapy","authors":"K. Warring-Davies, Martin J. Bland","doi":"10.2147/OAJCT.S9843","DOIUrl":null,"url":null,"abstract":"The empirical physiological formulae of the new continuous cardiac dynamic monitoring HeartSmart ® technology, which involves the use of a new inverse square rule of the heart, were investigated with pulmonary artery catheter (PAC) thermodilution in the estimation of CI in diverse patients. Clinical trial data collected from 268 adult surgery or intensive care patients requiring PAC placement were obtained from 7 NHS Trust hospitals, providing 2720 paired sets of CI estimations for comparison between HeartSmart ® and PAC thermodilution. For 95% of pairs of measurements, HeartSmart ® values were between 57% and 164% of PAC measure- ments; additionally, the larger limit of agreement between HeartSmart ® and PAC thermodilution (1.26 L min -1 ·m -2 ) suggests that HeartSmart ® agrees with PAC thermodilution as closely as PAC thermodilution agrees with itself. HeartSmart ® can also estimate CI in the extreme circumstances of shock/sepsis, as indicated by PAC thermodilution CI values that were hypo- or hyperdynamic based on systemic inflammatory response syndrome criteria. In CI measurements for hypo- or hyperdynamic values that were matched between HeartSmart ® and PAC thermodilution, the difference in total volumes and average CI measurements between the two methods was less than 5%. For unmatched hypo- or hyperdynamic values, the difference between total volumes and average CI measurements was less than 33% - an acceptable percentage of difference or error even for normal values of CI. HeartSmart ® tracked PAC thermodilution CI hypodynamic values 98.2% of the time and hyperdynamic values 97.6% of the time. These findings show that CI estimations provided by the HeartSmart ® empirical physiological formulae are comparable to those obtained using PAC thermodilution. HeartSmart ® removes many of the technical barriers that prevent the routine adoption and practice of early goal-directed therapy, and represents a simple, reliable method of estimating CI and other hemodynamic variables at the bedside or in departments other than the Intensive Care Unit.","PeriodicalId":19500,"journal":{"name":"Open Access Journal of Clinical Trials","volume":"2 1","pages":"115-123"},"PeriodicalIF":1.4000,"publicationDate":"2010-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OAJCT.S9843","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Access Journal of Clinical Trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OAJCT.S9843","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 5
Abstract
The empirical physiological formulae of the new continuous cardiac dynamic monitoring HeartSmart ® technology, which involves the use of a new inverse square rule of the heart, were investigated with pulmonary artery catheter (PAC) thermodilution in the estimation of CI in diverse patients. Clinical trial data collected from 268 adult surgery or intensive care patients requiring PAC placement were obtained from 7 NHS Trust hospitals, providing 2720 paired sets of CI estimations for comparison between HeartSmart ® and PAC thermodilution. For 95% of pairs of measurements, HeartSmart ® values were between 57% and 164% of PAC measure- ments; additionally, the larger limit of agreement between HeartSmart ® and PAC thermodilution (1.26 L min -1 ·m -2 ) suggests that HeartSmart ® agrees with PAC thermodilution as closely as PAC thermodilution agrees with itself. HeartSmart ® can also estimate CI in the extreme circumstances of shock/sepsis, as indicated by PAC thermodilution CI values that were hypo- or hyperdynamic based on systemic inflammatory response syndrome criteria. In CI measurements for hypo- or hyperdynamic values that were matched between HeartSmart ® and PAC thermodilution, the difference in total volumes and average CI measurements between the two methods was less than 5%. For unmatched hypo- or hyperdynamic values, the difference between total volumes and average CI measurements was less than 33% - an acceptable percentage of difference or error even for normal values of CI. HeartSmart ® tracked PAC thermodilution CI hypodynamic values 98.2% of the time and hyperdynamic values 97.6% of the time. These findings show that CI estimations provided by the HeartSmart ® empirical physiological formulae are comparable to those obtained using PAC thermodilution. HeartSmart ® removes many of the technical barriers that prevent the routine adoption and practice of early goal-directed therapy, and represents a simple, reliable method of estimating CI and other hemodynamic variables at the bedside or in departments other than the Intensive Care Unit.
新的连续心脏动态监测HeartSmart®技术的经验生理学公式,涉及到使用新的心脏平方反比法则,用肺动脉导管(PAC)热稀释来估计不同患者的CI。从7家NHS信托医院收集了268名需要放置PAC的成人手术或重症监护患者的临床试验数据,提供了2720组配对的CI估计,用于比较HeartSmart®和PAC热稀释。对于95%的测量对,HeartSmart®的值在57%到164%的PAC测量值之间;此外,HeartSmart®和PAC热修正之间的最大一致限度(1.26 L min -1·m -2)表明HeartSmart®与PAC热修正的一致程度与PAC热修正本身的一致程度一样高。HeartSmart®还可以估计休克/败血症极端情况下的CI,根据全身炎症反应综合征标准,PAC热稀释CI值为低动态或高动态。在HeartSmart®和PAC热调节相匹配的低动力或高动力值CI测量中,两种方法之间的总体积和平均CI测量差异小于5%。对于不匹配的低动力或高动力值,总体积和平均CI测量值之间的差异小于33%——即使对于正常CI值,差异或误差的百分比也是可以接受的。HeartSmart®跟踪PAC热稀释CI低动力值98.2%的时间和高动力值97.6%的时间。这些发现表明,由HeartSmart®经验生理公式提供的CI估计值与使用PAC热稀释获得的估计值相当。HeartSmart®消除了许多阻碍早期目标导向治疗常规采用和实践的技术障碍,并代表了一种简单、可靠的方法来估计床边或重症监护病房以外科室的CI和其他血液动力学变量。